<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598570</url>
  </required_header>
  <id_info>
    <org_study_id>M15-460</org_study_id>
    <nct_id>NCT02598570</nct_id>
  </id_info>
  <brief_title>Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese
      participants with relapsed or refractory lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting Treatment-emergent Adverse Events</measure>
    <time_frame>Throughout the study for approximately 2 years</time_frame>
    <description>The number of participants reporting treatment-emergent adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Duvelisib</measure>
    <time_frame>Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Duvelisib</measure>
    <time_frame>Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib</measure>
    <time_frame>Cycle 1 Day 1, 8, 15, and 22 and on Day 1 of Cycles 2 - 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Throughout the study for approximately 2 years</time_frame>
    <description>Overall Response Rate is defined as the proportion of participants with a confirmed response of complete (CR) or partial response (PR) based on the revised International Working Group (IWG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Throughout the study for approximately 2 years</time_frame>
    <description>Overall survival is defined as the duration in weeks from the date of the first dose of study treatment until the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Throughout the study for approximately 2 years</time_frame>
    <description>Progression free survival is defined as the time from the date of the first dose of study treatment to the first documentation of progressive disease (PD) or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>duvelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib will be administered orally as a fixed dose in 28-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duvelisib</intervention_name>
    <description>Duvelisib will be administered orally as a fixed dose in 28-day cycles.</description>
    <arm_group_label>duvelisib</arm_group_label>
    <other_name>IPI-145</other_name>
    <other_name>ABBV-954</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lymphoma (excluding lymphoblastic lymphoma)

          -  Progressed during, refractory to, intolerant of, or ineligible for established
             therapy, or has a disease for which there is no established therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status lower than or equal to 2

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Any prior treatment with a PI3K inhibitor or Bruton's tyrosine kinase (BTK) inhibitor

          -  Ongoing treatment with chronic immune-suppressants

          -  Overt CNS lymphoma

          -  Inadequate hepatic, bone marrow, or renal function

          -  History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or mechanical control within the last 6 months

          -  Venous thromboembolic event requiring anticoagulation

          -  Presence of active systemic infection within 72 hours of treatment

          -  Human immunodeficiency virus (HIV) infection

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141826</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141595</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141594</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed Lymphoma</keyword>
  <keyword>Phosphoinositide 3-kinase (PI3K) Inhibitor</keyword>
  <keyword>Duvelisib</keyword>
  <keyword>Japanese</keyword>
  <keyword>Refractory Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

